Loading people...
Kevin Dai is a Managing Director at Vivo Capital based in the Greater San Francisco Bay Area, where he focuses on healthcare, biotechnology, and life sciences investments. Before joining the global healthcare investment firm, he spent three years operating as a Clinical Oncology Pharmacy Specialist in hematology at the Memorial Sloan Kettering Cancer Center. During his tenure in this clinical capacity, he actively managed leukemia clinical trials and directed specialized patient care protocols. Transitioning into the financial sector, Dai gained institutional experience working in sell-side equity research, analyzing public healthcare markets before moving to venture capital. He holds a Doctor of Pharmacy degree alongside a Board Certified Oncology Pharmacist designation. His current investment strategy leverages his specialized clinical oncology background to evaluate emerging pharmaceutical and biotechnology companies for both public and private market opportunities.
Kevin Dai is a distinguished Managing Director at Vivo Capital, a leading global investment firm dedicated exclusively to the healthcare sector. In his pivotal role, Mr. Dai is responsible for spearheading the identification, evaluation, and execution of strategic investment opportunities across the vast landscape of life sciences and medical technology. His work is crucial in advancing Vivo Capital's mission to support groundbreaking companies that are developing innovative solutions to address critical unmet medical needs worldwide.
At Vivo Capital, Kevin Dai's investment focus spans a broad spectrum of healthcare sub-sectors. This includes cutting-edge biotechnology firms developing novel therapeutics, pharmaceutical companies with transformative drug pipelines, and medical device innovators creating next-generation tools for diagnosis and treatment. He also keenly evaluates opportunities in diagnostics, digital health platforms, and healthcare services that promise to enhance patient care and operational efficiency. His expertise lies in discerning the scientific merit, market potential, and commercial viability of these ventures, ensuring that Vivo Capital invests in companies with the highest potential for impact and return.
Before joining Vivo Capital, Kevin Dai cultivated a robust career background that equipped him with a profound understanding of both the financial and scientific intricacies of the healthcare industry. While specific details of his prior roles are not publicly detailed, professionals in his position typically bring a wealth of experience from areas such as investment banking, management consulting, or direct operational roles within pharmaceutical or biotech companies. This diverse experience provides him with a unique perspective, enabling him to effectively guide portfolio companies through various stages of growth, from early-stage development to market commercialization.
Kevin Dai's contributions are integral to Vivo Capital's impressive portfolio, which includes numerous successful companies that have brought significant advancements to patient care. While individual investment specifics are often confidential, his involvement helps shape the strategic direction and operational excellence of these portfolio companies, fostering their growth and ultimately delivering value to both patients and investors. His commitment to fostering innovation underscores Vivo Capital's reputation as a key player in global healthcare investment, continually seeking out and nurturing the next generation of healthcare leaders. Through his leadership, Kevin Dai continues to drive Vivo Capital's commitment to investing in the future of health.
Kevin Dai is a Managing Director at Vivo Capital, a prominent global investment firm focused exclusively on the healthcare sector. He plays a key role in identifying and managing strategic investments in life sciences and medical technology companies.
Kevin Dai invests in a wide range of healthcare sub-sectors through Vivo Capital, including biotechnology, pharmaceuticals, medical devices, diagnostics, digital health, and healthcare services. His focus is on innovative companies addressing unmet medical needs.
Kevin Dai works at Vivo Capital, a leading global healthcare investment firm. Vivo Capital has offices in Palo Alto, Beijing, and Shanghai, among other locations.
